Zobrazeno 1 - 10
of 114
pro vyhledávání: '"Helle, Anita"'
Autor:
Helle, Anita
Publikováno v:
South Atlantic Review, 1996 Apr 01. 61(2), 51-68.
Externí odkaz:
https://www.jstor.org/stable/3201410
Autor:
DeShazer, Mary K., Helle, Anita
Publikováno v:
Tulsa Studies in Women's Literature, 2013 Oct 01. 32/33(2/1), 7-23.
Externí odkaz:
https://www.jstor.org/stable/43653274
Autor:
Helle, Anita
Publikováno v:
College Composition and Communication, 2009 Dec 01. 61(2), 388-388.
Externí odkaz:
https://www.jstor.org/stable/40593468
Autor:
Helle, Anita
Publikováno v:
NWSA Journal, 1994 Oct 01. 6(3), 434-441.
Externí odkaz:
https://www.jstor.org/stable/4316354
Autor:
Per Pfeiffer, K R Schønnemann, Stine Braendegaard Winther, Mathilde Weisz Ejlsmark, Merete Krogh, Jon Kroll Bjerregaard, Helle Anita Jensen
Publikováno v:
Winther, S B, Bjerregaard, J K, Schonnemann, K R, Ejlsmark, M W, Krogh, M, Jensen, H A & Pfeiffer, P 2018, ' S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma ', Cancer Chemotherapy and Pharmacology, vol. 81, no. 3, pp. 573–578 . https://doi.org/10.1007/s00280-018-3528-5
PURPOSE: Gemcitabine has been standard of care in advanced pancreatic adenocarcinomas (PC) for almost two decades. Randomized, primarily Japanese, studies have shown promising efficacy when combined with S-1 (GemS-1); however, no data are published i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9970c5b1ee7299ad820c5800d2fedc51
https://doi.org/10.1007/s00280-018-3528-5
https://doi.org/10.1007/s00280-018-3528-5
Autor:
Helle Anita Jensen, Kanita Zubcevic, Camilla Qvortrup, Lene Weber Vestermark, Stine Braendegaard Winther, Halfdan Sorbye, Merete Krogh, Per Pfeiffer
Publikováno v:
Winther, S B, Zubcevic, K, Qvortrup, C, Vestermark, L W, Jensen, H A, Krogh, M, Sorbye, H, Pfeiffer, P & Academy of Geriatric Cancer Research (AgeCare) 2016, ' Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC) : Findings from an observational chart review ', Acta Oncologica, vol. 55, no. 7, pp. 881-885 . https://doi.org/10.3109/0284186X.2016.1161825
Background: An aging population will increase the number of older patients with metastatic colorectal cancer (mCRC). However, there is limited knowledge about treatment in older patients as they are under-represented in clinical trials. The oral fluo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16ddda3333de3d81b5bb9bdb73d523d8
https://doi.org/10.3109/0284186x.2016.1161825
https://doi.org/10.3109/0284186x.2016.1161825
Autor:
Merete Krogh, Jon Kroll Bjerregaard, Helle Anita Jensen, Camilla Qvortrup, Lene Weber Vestermark, Per Pfeiffer, Katrine R. Schoennemann
Publikováno v:
Pfeiffer, P, Qvortrup, C, Krogh, M, Schoennemann, K, Weber Vestermark, L, Jensen, H A & Kroll Bjerregaard, J 2017, ' S-1 in combination with docetaxel and oxaliplatin in patients with advanced gastro-esophageal adenocarcinoma : two parallel phase 1/2a studies ', Acta Oncologica, vol. 56, no. 1, pp. 46-51 . https://doi.org/10.1080/0284186X.2016.1257865
BACKGROUND: Docetaxel in combination with cisplatin and 5-fluorouracil (5-FU) is one of several standard chemotherapy regimens for patients with advanced gastro-esophageal adenocarcinoma (aGEA) in Europe. To enable outpatient treatment, we evaluated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e8fb05c5b6dae846bf6e75c164c1306
https://portal.findresearcher.sdu.dk/da/publications/27e1d5a9-33ea-46a8-895b-242f9a039952
https://portal.findresearcher.sdu.dk/da/publications/27e1d5a9-33ea-46a8-895b-242f9a039952
Autor:
BRØNS, HELLE ANITA
Publikováno v:
The Burlington Magazine, 2015 Oct 01. 157(1351), 715-715.
Externí odkaz:
http://www.jstor.org/stable/43858176